

11/24/00
jc803 U.S. PTO

BOX PATENT APPLICATION
Attorney Docket No. 24460

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Oren BECKER; Maya TOPF

Serial No. NOT YET ASSIGNED

Filed: November 24, 2000

For: **A METHOD AND SYSTEM FOR PREDICTING AMINO ACID SEQUENCES
COMPATIBLE WITH A SPECIFIED THREE DIMENSIONAL STRUCTURE**

TRANSMITTAL LETTER

Commissioner of Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) PTO Form-1082
- (3) 42 page Application consisting of:
 - 30 pages Textual Specification
 - 4 pages of 21 claims
 - 1 page containing the Abstract of the Disclosure
 - 7 sheets drawings
- (4) Preliminary Amendment
- (5) Executed Declaration/Power of Attorney
- (6) Assignment and Recordation Cover Sheet
- (7) Check No. 13841 \$ 373.00 for filing fee as a small entity
- (8) Check No. 13842 \$ 40.00 for recordation fee
- (9) Postcard for early notification of serial number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: 

Gary M. Nath
Registration No. 26,965
Lee C. Heiman
Registration No. 41,827
Customer No. 20529

November 24
Date: ~~October~~ 24, 2000
NATH & ASSOCIATES PLLC
1030th 15th Street, NW - 6th Floor
Washington, D.C. 20005
GMN/LCH/dd:APPL.trans

jc841 U.S. PTO
09/118425
11/24/00

09718425 118400

NATH & ASSOCIATES PLLC

Attorneys at Law

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005-1503

TELEPHONE (202) 775-8383

(202) 775-9393

FACSIMILE (202) 775-8396

(202) 822-9409

E-Mail: ip@nathlaw.com

Web: www.nathlaw.com

Gary M. Nath (DC, NJ)

Harold L. Novick (DC, MD)

Todd L. Juneau (DC, IL)

Irvin A. Lavine (DC), Retired*

Donald M. Sandler (MD), Retired*

*Patent, Trademark and Copyright Causes
Unfair Competition, Trade Secrets,
Licensing and Litigation*

**Practice limited to Matters and Proceedings
before Federal Courts and Agencies; not Admitted
in DC*

Michelle L. Hartland (VA)*

Lee C. Heiman (CA)*

Jerald L. Meyer (VA)*

Paul A. Sacher (MD)*

Marvin C. Berkowitz (GA)*

Tanya E. Jankovic (MD)*

Joshua B. Goldberg (VA)*

Nahied K. Usman (VA)*

Alvin E. Tanenholtz

Deborah H. Yellin

Roger C. Hahn

**** Registered Patent Agent: not Admitted in DC**

FORM PTO-1082

TRANSMITTAL FOR NEW U.S. PATENT APPLICATION

Commissioner of Patents
Washington, D.C. 20231

Re: New U.S. Patent Application
For: **A METHOD AND SYSTEM FOR PREDICTING AMINO
ACID SEQUENCES COMPATIBLE WITH A
SPECIFIED THREE DIMENSIONAL STRUCTURE**
Inventor(s): Oren BECKER
Maya TOPF
Attorney Docket: 244360

Sir:

Attached hereto is the application identified above, including:

42 Pages Application Consisting of:
30 Pages of Textual Specification
4 Pages of 21 Claims
1 Abstract of the Disclosure
7 Sheets of drawings.
☒ Executed Inventor's Declaration
☐ Unexecuted Inventor's Declaration
☒ Assignment and cover sheet
☐ Priority Document


The Government filing fee* is calculated as follows:

Total Claims	<u>22</u> - 20 = <u>2</u>	x \$18.00 =	<u>\$36.00</u>
Independent Claims	<u>1</u> - 3 = <u>0</u>	x \$78.00 =	<u>\$0.00</u>
Base Fee			<u>\$710.00</u>
Multiple Dependent Claim Fee (\$260.00)			<u>\$ 0.00</u>
Subtotal			<u>\$746.00</u>
TOTAL FILING FEE*			
(accounting for small entity status)			<u>\$373.00</u>

- X Reduced by one-half, as applicant(s) is/are a "small entity".
- X Foreign priority is claimed under 35 U.S.C. § 119 from ISRAEL Patent Application(s) No. 137886 dated August 16, 2000.
- X Priority document(s) will be submitted at a later date.
- ___ Priority document(s) is/are submitted herewith.
- ___ Executed Declaration(s) will be submitted at a later date pursuant to 37 CFR § 1.41 and § 1.53, with an appropriate surcharge under 37 CFR § 1.16(e).
- X Formal drawing(s) is/are attached.
- ___ Formal drawing(s) will be submitted at a later date.
- X Assignment document(s) is/are submitted herewith; the recordation fee of \$40.00 per document is enclosed herewith.
- ___ Assignment document will be submitted at a later date.
- ___ A Verified Translation will be submitted at a later date.
- ___ No payment is enclosed at this time. Full payment will be made when the executed Declaration is submitted.
- X Submitted herewith is a check in the amount of \$373.00. The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC



Gary M. Nath
Registration No. 26,965
Lee C. Heiman
Registration No. 41,827
Customer No. 20529

Date: November 24, 2000
NATH & ASSOCIATES PLLC
1030 15TH Street NW - 6th Floor
Washington, D.C. 20005
(202)-775-8383
GMN/LCH/dd (1082)

2004 OCT 24 10 46 AM

BOX PATENT APPLICATION
Attorney Docket No. 24460

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Oren BECKER; Maya TOPF

Serial No. NOT YET ASSIGNED

Filed: November 24, 2000

For: **A METHOD AND SYSTEM FOR PREDICTING AMINO ACID SEQUENCES
COMPATIBLE WITH A SPECIFIED THREE DIMENSIONAL STRUCTURE**

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

Before calculating the filing fee for the above identified application, please enter the following amendments:

IN THE CLAIMS:

Claim 17, line 1, delete "or 16".

Claim 20, line 1, delete "19 or 20" and insert in lieu thereof -- 18 --.

Please add the following claim:

22. The method as claimed in claim 16, wherein said *de novo* amino acid sequence stabilized said 3D structure, as compared to the native amino acid sequence.

DOCKET # 24460


REMARKS

The above amendments have been made to remove multiple dependencies from the claims, and claim 22 has been added to compensate for the subject matter deleted from heretofore multiple dependent claim 17. No new matter has been added.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By:


Gary M. Nath
Registration No. 26,965
Lee C. Heiman
Registration No. 41,827
Customer No. 20529

Date: November 24, 2000
NATH & ASSOCIATES PLLC
1030th Street, NW - 6th Floor
Washington, D.C. 20005
GMN/LCH/dd:AMENDpreml

00437-32460

A METHOD AND SYSTEM FOR PREDICTING AMINO ACID SEQUENCES COMPATIBLE WITH A SPECIFIED THREE DIMENSIONAL STRUCTURE

FIELD OF THE INVENTION

This invention relates to the field of protein design and more particularly to the field of inverse-protein folding for *de novo* protein design.

PRIOR ART

5 The following is a list of prior art which is considered to be pertinent for describing the state of the art in the field of the invention. Acknowledgement of these references herein will be made by indicating the number from their list below within brackets.

1. Desjarlais J.R. & Handel T.M. *Protein Science* 4:2006-2018 (1995).
- 10 2. Lazar G.A. et al. *Protein Sci.* 6:1167-1178 (1997).
3. Hellinga H.W. et al. *J. Mol. Biol.* 222:763-785 (1991).
4. Hurley H.W. et al. *J. Mol. Biol.* 224:1143-1154 (1992).
5. Harbury P.B. et al. *PNAS USA* 92:8408-8412 (1995).
6. Klemba M. et al. *Nat. Struc. Biol.* 2:368-373 (1995).
- 15 7. Nautiyal S. et al. *Biochemistry* 34:11645-11651 (1995).
8. Betz S.F. et al. *Biochemistry* 35:6955-6962 (1996).
9. Dahiyat B. I. et al. *Protein Science* 5:895-903 (1996).
10. Jones D.T. et al. *Protein Science* 3:567-574 (1994).
11. Kono H & Doi J. *Proteins: Structure, Function and Genetics* 19:224-255 (1994).
- 20 12. Desmet J. et al. *Nature* 356:539-542 (1992).
13. Dahiyat B.I. & Mayo S.L. *Protein Sci.* 5:895-903 (1997).

14. Dahiyat B.I. & Mayo S.L. *Proc. Natl. Acad. Sci. USA* 94:10172-10177 (1997).
15. Malakauskas S. M. and Mayo S. L. *Nat. Struct. Biol.* 5:470-475 (1998).

BACKGROUND OF THE INVENTION

Depending on the primary structure and the environment, proteins fold into a
5 three-dimensional (3D) structure containing recurring motives which pack together to
form the 3D structure, the most common motives observed being the α -helix, β -turn,
parallel and anti-parallel β -sheets.

The 3D structure of a protein may be characterized as having internal surfaces
being the areas buried within the structure and thus directed away from the aqueous
10 environment in which the protein is normally found; external surfaces being the areas
exposed to the aqueous environment and intermediate or boundary surfaces. Through
the study of many natural proteins, researches have discovered that hydrophobic
residues are most frequently found on the internal surface of water soluble protein
molecules while hydrophilic residues are most frequently found on the external protein
15 surfaces.

It was established that while the biological properties of a protein depend
directly on the protein's 3D conformation, only some of the information in the protein's
sequence is necessary to specify its fold, i.e. a given native structure may be formed
from many different sequences [Lau K.F. and Dill K. A. *PNAS USA* 87:638-652
20 (1990)]. The different sequences compatible with a given 3D structure are referred to
as the structure's *Sequence Space*. The finding that a number of amino acid sequences
may fold into the same basic 3D structure, have focused attention on a new field
commonly referred to as the "inverse protein folding" or "*de novo* protein design".
While conventional protein folding methods are trying to predict the tertiary structure
25 of a protein from their amino acids sequence, protein design methods are looking for a
sequence that will stabilize a given fold, by using the same principals.

Reports of experimentally predicted amino acid sequences which adopt an intended fold and possess physical properties similar at least in part to those of natural proteins are appearing with increasing frequency [Kortemme T. *et al. Science* 281:253-256 (1998); Kurda Y. *et al. J. Mol. Biol.* 236:862-868 (1994); Quinn T. P. *et al PNAS USA* 91:8747-8751 (1994); Fezoui Y. *et al PNAS USA* 91:3675-3679 (1994); Betz S.F. *et al Curr. Opin. Struc. Biol.* 5:457-463 (1995); Raleigh D.P. *et al J. Am. Chem. Soc.* 117:755-7559 (1995); Regan L. & DeGardo W.F. *Science* 241:976-978 (1988); Hecht M.H. *et al. Science* 249:884-891; Beauregard M. *et al. Protein Eng.* 4:745-749 (1991) Kamtekar S. *et al Science* 262:1680-1685 (1993)]. These studies have been predominantly experimental and rely on knowledge of the physical properties that determine the protein's structure, such as the patterns of hydrophobic and hydrophilic residues in the sequence.

Several groups have applied an experimentally tested systematic, quantitative methods to protein design with the goal of developing general design algorithms. Desjarlais and Handel ⁽¹⁾ were the first to experimentally investigate predictions generated by genetic algorithms (GA). They have developed ROC ("Repacking of Cores"), a computational program that attempts to find novel core sequences given the backbone structure of the protein of interest. In different, however related, work, a modification of the ROC was used on the secondary structure of the $\alpha\beta$ protein ubiquitin⁽²⁾. The program used a genetic algorithm to optimize the search for alternative core structures for a given protein. Other experimentally tested methods applied with respect to protein design are described elsewhere⁽³⁻¹¹⁾. Thus, in some cases, uniquely folded and even functional globular proteins may be obtained using highly simplified minimally designed cores. The algorithms consider the spatial positioning and steric complement of side chains by explicitly modeling the atoms of sequences under consideration. However, despite the success of these studies, a full predictive understanding of hydrophobic core packing in proteins has not yet been fully realized, and *de novo* design of stable and unique proteins, remains a challenging problem.

A major breakthrough was achieved by the Dead-End Elimination (DEE) algorithm by Desmet *et al.*⁽¹²⁾, which was originally developed for homology modeling. DEE finds and eliminates rotamers that are mathematically provable to be inconsistent (or dead ending) with the global minimum energy solution of the system.

5 Dahiya and Mayo⁽¹²⁾ further adapted the algorithm by Desmet for the explicit exploration of sequence space using semi-empirical potential functions and stereochemical constraints, which intended to capture most of the known contributions of protein stability. In their design strategy they succeeded in expanding the range of computational protein design to residues of all parts of the protein: the buried core, the
10 solvent-exposed surface, and the boundary between core and surface.

SUMMARY OF THE INVENTION

In accordance with a first of its aspects, the present invention relates to a computer-implemented method for predicting at least one amino acid sequence compatible with a predefined three-dimensional (3D) structure, which method comprises
15 the steps of:-

- a) providing a coordinate set representing the backbone of said 3D structure;
- b) constructing a reduced virtual representation for the 3D structure provided in step (a);
- c) determining for each position along the virtual structure representation provided
20 in step (b) its solvent accessibility;
- d) constructing an initial amino acid sequence by assigning each position along the sequence an amino acid residue selected randomly from a predefined group of amino acids having a solvent accessibility (SA) compatible with the solvent accessibility determined for each position;
- 25 e) randomly selecting one or more positions along the sequence provided in step (d) and applying on each position a Monte-Carlo simulation in sequence space and rotamer space, said simulation comprising one or more scoring function

calculating steps which include:-

- i) randomly selecting one or more amino acid residues of the same solvent accessibility as that defined for said position to provide a mutation;
- ii) calculating an energy scoring function for each possible rotamer of each amino acid residue provided in step (i) based on their said reduced virtual representation;
- iii) selecting the lowest scoring rotamer or when more than one amino acid is manipulated simultaneously, selecting the lowest scoring rotamer combination;
- iv) determining whether to accept or reject the mutation with the rotamer or rotamer combination selected in step (iii), by applying, for example, the Metropolis algorithm; and
- v) assigning the amino acid residue or residues and their respective selected rotamer or rotamer combinations selected in step (iii) to said position/s and moving to another position along the sequence;

said simulation steps are repeated until for each position along said sequence, the residue and residue's rotamer with the lowest score is selected, to obtain a virtually represented amino acid sequence with the lowest total score;

- f) expanding the reduced representation of the amino acid sequence obtained in step (e) to its corresponding all-atom sequence representation thereby obtaining an amino acid sequence compatible with said predefined 3D structure; and
- g) optionally, creating a computer output of the expanded all-atom representation of the amino acid sequence obtained in step (f).

According to a second aspect, the invention provides amino acid sequences which fold into predefined 3D structures, the amino acid sequences being obtained by the method of the present invention.

Furthermore, the invention provides, in accordance with another of its aspects, a computer-based system for predicting an amino acid sequence compatible with a predefined 3D structure comprising a computer device equipped with:- (a) input apparatus, such as a keyboard, for specifying said 3D structure; (b) a first memory for storing the specified 3D structure; (c) a second memory having a stored thereon an application program which when running, provides at least one amino acid sequence compatible with the specified 3D structure; (d) a third memory for storing the at least one amino acid sequence obtained; (e) a processor coupled to said input means, and to said first, second and third memories for representation of said amino acid sequence; and (f) optionally, a display unit coupled to said processing means for displaying the amino acid sequence.

The specified 3D structure may be obtained from a data bank accessible through the network or available on diskette, CD or tape which is then downloaded onto the first memory module. Thus, the term "*input apparatus*" signifies also any suitable means for connecting to a network and retrieving from available databanks accessible thereby the desired 3D structure. Furthermore, *input apparatus* also refers to any apparatus enabling retrieving such sequences from computer readable mediums, e.g. diskettes, CDs, tapes etc.

The processor may be any computer device stored with an application utility, which when running on the computer device, enables the processing of the stored data so as to provide a an amino acid sequence which substantially folds into a desired 3D structure, i.e. that specified in step (a) of the method of the invention, such a computer device includes, *inter alia*, a private computer (PC, either Windows or Linux OS), workstation computers (UNIX), a computer-cluster or Super-computers.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, some non-limiting examples will now be described, with reference to the accompanying drawings, in which:

Fig. 1 shows the energy profile obtained for the *Zif268* backbone by the system of the invention, during 10^5 iterations, at three temperatures: 1000K (continuous line), 500K (broken line) and 100K (dotted line). The temperature remained constant during the simulation. The energy of the initial random sequence, before simulation initiated
5 was +204kcal/mol.

Fig 2 shows the energy profile obtained for the *Zif268* backbone by the system of the invention during 10^5 iterations, at three maximal temperatures: 1000K (continuous line), 500K (broken line) and 100K (dotted line) using an annealing temperature profile, with periodicity of 500 Monte Carlo steps during which the
10 temperature is gradually decreased from its initial value, to zero, and then set up again to its initial value for another cycle. The energy of the initial random sequence, before the simulation started was +204kcal/mol.

Fig 3 shows the energies of the 20 lowest sequences generated by the algorithm at different simulation lengths and different temperatures, using an annealing
15 temperature profile with periodicity of 500 Monte Carlo steps.

Fig 4A-4C shows the three dimensional structure crystallography of *Zif268* (Fig. 4A) compared with the 3D structure of the designed proteins A and B (Figs. 4B and 4C, respectively).

Fig 5A-5C shows the 3D crystallography structure of *Zif268* (Fig 5A)
20 compared with the three dimensional structure of the designed proteins A and B (Figs 5B and 5C, respectively), after minimization of their side chains, displayed by spheres sized to the van der Walls radii of the atoms (not including hydrogens).

Fig 6 shows a diagram of G β 1 solvent accessibility, according to the present invention's methodology (black columns) and according to D&M (gray columns).

Fig 7A-7B shows the 3D structure of G β 1 overlaid on that of the designed
25 sequence C from two different angles (Fig. 7A and 7B).

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates in general to a method of predicting one or more amino acids compatible with a predefined 3D structure. The predefined 3D structure may be that of a native protein, polypeptide, a biologically functional derivative or
5 fraction of the native protein or polypeptide or any other biologically functional polymer, the determination of its lowest free-energy-structure is desirable.

In the current disclosure, above and below, the terms "*amino acid sequence*", "*primary sequence*" and other similar terms or derivation thereof, may be used interchangeably. These terms, as used herein, refer to an amino acid sequence of a
10 protein or polypeptide. The primary structure of a protein or polypeptide is the amino acid sequence wherein the location of disulfide bridges, if any exist, are indicated. The primary structure is thus a complete description of the covalent connections within the polymer.

The term "*amino acid*" as used herein above and below means any organic
15 compound possessing one or more amino groups and one or more carboxyl groups. Such amino acids may be naturally occurring L-amino acids, their corresponding D-isomers, synthetic amino acids, or any other variations of the same. Within this context, the term *variant* should be understood as including all possible modifications of the naturally occurring or synthetic amino acids including deletions, insertions,
20 substitutions of group/s therein. By the term "*amino acid residue*", it should be understood an amino acid, as defined above, which forms part of a chain, the chain consisting two or more amino acid units.

The coordinate set including the dihedral angles and specific bonds within the predefined 3D structure, may be obtained from any suitable databank known to those
25 versed in the art, such as the Protein Data Bank (PDB, supported by the RCSB consortium) and is preferably provided in a computer readable form to enable its easy input into the system of the invention. Alternatively, the 3D structure may be defined at will, without relying on any known 3D structure of any specific protein. Such novel 3D

structures will agree with the general structure constraints of polypeptides, such as backbone geometries, as known to those versed in the art.

According to the method of the invention, a reduced virtual representation is first constructed for the predefined 3D structure. The reduced representation may be obtained by the methodology originally developed by Herzyk and Hubbard for use with dynamic simulated annealing [Herzyk P. and Hubbard R.E. Proteins 17:310-324 (1993)]. According to this methodology, the amino acids are represented by virtual spherical atoms, wherein the main chain of the protein, polypeptide or any other suitable polymer is represented by one virtual atom per residue located at the C α position and the side chains are represented by one or more additional virtual atoms. The number of additional virtual atoms depends on the size and chemical composition of the specific side chain.

Typically, one additional virtual atom will represent amino acid residues having only a β side chain heavy atom or β and γ side chains heavy atoms, e.g. serine (Ser, S), threonine (Thr, T), alanine (Ala, A), valine (Val, V), cysteine (Cys, C). Proline will also consist part of this group as its C δ heavy atom is very close to its C α and C β atoms. Two additional virtual atoms will represent amino acid residues having β , γ and δ side chains heavy atoms, β being represented by one virtual atom and γ and δ together by another virtual atom. It should be noted that the representation with two additional side chain virtual atoms exhibit rotational flexibility around the C β -C γ bond, e.g. histidine (His, H), aspartic acid (Asp, D), asparagine (Asn, N), tyrosine (Tyr, Y), leucine (Leu, L), isoleucine (Ile, I), phenylalanine (Phe, F) and methionine (Met, M). Three additional virtual atoms will represent amino acid such as lysine (Lys, L), arginine (Arg, R), glutamic acid (Glu, E), Glutamine (Gln, Q) and tryptophane (Trp, W). Evidently, amino acids, other than the naturally occurring amino acids (e.g. chemical modifications or synthetic variations thereof) may be presented by virtual atoms in a similar manner.

After constructing the reduced representation for the 3D structure provided, the extent of solvent accessibility at each position along the 3D structure is determined. In

principal, *solvent accessibility* (SA) is a feature assigned for each position along the chain of the folded protein or polypeptide. Each position is categorized as being either *buried* within the 3D structure (in an internal surface), *exposed* (part of an external surface) or within a boundary surface (*intermediate* position).

5 According to one preferred embodiment of the invention, the SA is determined by surrounding the reduced representation of the protein with a grid and calculating the number of grid points that fall into the intersection volume of the volume of every virtual atom and the volume of its neighbor virtual atom (the volume determined according to the adequate van der Waals radius [Bernstein F. C. *et al.* J. Mol. Biol.
10 112:535-542 (1977)]). However, it should be clear that other ways of determining an amino acid's SA can be employed as may be known to the man versed in the art.

Each type of position, i.e. buried, exposed or intermediate, may be occupied by several amino acid residues. Hydrophobic amino acids, being able to form a hydrophobic core, are assigned to the buried positions of the 3D structure, while
15 hydrophilic amino acids are assigned for the solvent-exposed positions. Boundary positions, between those two environments can be occupied by both types of amino acids.

According to one particular embodiment of the invention, the buried positions may be occupied by amino acids selected from the group consisting of Ala, Tyr, Trp,
20 Val, Leu, Ile, Phe, Met, Cys, Pro, Gly and variants thereof, all of which being hydrophobic in nature.

The exposed positions may be occupied by amino acid residues selected from the group consisting of Lys, Arg, His, Glu, Asp, Gln, Asn, Ser, Thr and variants thereof all of which being hydrophilic in nature.

25 The positions having assigned an intermediate level of SA, may be occupied by all types of amino acids, particularly those which serve in nature as building blocks for proteins, i.e. Pro, Lys, Arg, His, Glu, Asp, Gln, Asn, Ser, Thr, Gly, Ala, Tyr, Trp, Val, Leu, Ile, Phe, Met, Cys and variants thereof.

It should be noted, however, that the above classification of the buried, intermediate and exposed residues is only one example of classification and these groups may be changes.

Special assignment of patterns may be set for particular positions in the protein's 3D structure that deviate from the general assignment based on SA, such assignment may be introduced, for example, to preserve buried salt bridges.

After assigning each position with its characteristic SA (1) an amino acid for every $C\alpha$ position is selected randomly, taking into account the solvent accessibility of that position (buried, exposed or intermediate). Alternatively, this selection may be applied only to a sub-set of the polypeptide's amino acid residue, leaving the other positions fixed throughout the design process; (2) the appropriate bonds and angles of the protein's reduced representation are assigned based on the coordinate set provided; and (3) one of the physically permissible rotamers that characterizes each of the amino acids is assigned.

A scoring function is applied to evaluate the effect of changing the amino acid sequence and residue rotamer for a given 3D backbone structure. The scoring function used according to the present invention has two main contributions: a residue-residue interaction term and a residue's secondary-structure propensity term. The interaction part of the scoring function is based in part on the Lenard-Jones like potential function, multiplied by the effective attractive inter-residue contact energies (ϵ_{ij}). The energy is summed over all possible pairs of residues in the protein where the energy between each pair residues is a sum of the interaction energies between all possible pairs of virtual atoms except for the energy between two neighboring $C\alpha$ virtual atoms that do not contribute to the interaction. Since each side chain is represented by one or more virtual atoms, the energy contribution of each residue-residue pair is divided among the virtual atoms such that the sum over energy contributions of the virtual atom pairs (one from each residue) equals the effective residue-residue interaction. The Lenard-Jones potential function is modified to make the effect of repulsion smaller (because the virtual atoms are 'softer' than real atoms).

The effective contact energies between two amino acids may be, for example, those calculated by Miyazawa and Jernigan [Miyazawa S. and Jernigan R.L. J. Mol. Biol. 256:623-644 (1996)]. The basic assumption on which the contact energies are calculated according to this model is that the average characteristics of residue-residue contacts, observed in a large number of crystal structures of globular proteins, represents the actual intrinsic inter-residue close contacts of protein structures.

Secondary structure propensities are also included in the scoring function. To this end, the total energy score of the protein is calculated by adding a residue specific "potential" for α -helical and β sheet states. These terms may be, for example, those calculated by Bahar *et al.* [Bahar I. *et al.* Proteins 29:292-308 (1997)]. These so-called potentials are added only if the residue is situated in a α -helical or a β -sheet regions of the 3D backbone template, according to the secondary structure of the designed protein or polypeptide.

The scoring function is applied as part of a Monte Carlo simulation which combines a search in the sequence space for amino acid residues and in the specific rotamer space of each residue. This process provides the system with the *optimal sequence* for a given backbone. The term "*optimal sequence*" refers to an amino acid sequence compatible with the predefined 3D structure and having the lowest total score.

The term "*Sequence space*" refers to the total number of possible different sequences for a given number of different residues and a given number of residues in the protein, polypeptide or any other appropriate polymer, e.g. for a protein of 100 residues, composed of 20 different amino acids, the sequence space will contain 20^{100} possible sequences. The term "*Rotamer space*" refers to the total number of physically permissible conformations for a residue in a given amino acid sequence.

The advantage of the combined reduced representation of the side chains and the grouping of amino acids and structure sites according to the solvent accessibility relies in the high efficiency of searching through both sequence space and rotamer space. The

combined simplifications, dramatically reduce the search space, while retaining a physically reasonable representation that can accurately account for rotamer flexibility.

The search in sequence space begins when up to three positions along the protein are simultaneously randomly selected and replaced with different amino acids (each replacement referred to as a 'mutant' in that specific 'trial configuration'). The replacing amino acids are selected randomly from the group of amino acids having the same characteristics (buried, exposed or intermediate) as defined for the specific replaced positions to form the 'mutant'. If any of the new mutation residues has more than one virtual side chain atom, a search in rotamer space begins by calculating the total energy score of the new sequence for each and every allowed rotamers or rotamer combinations of the mutated amino acids (not all rotamers are allowed, as described by Ponder and Richards [Ponder J.W and Richards F. M. J. Mol. Biol. 193(4):775-791 (1987)]). The energy score difference ΔE , between the lowest energy score of the trial configuration being the lowest energy score among all allowed rotamers of the new mutant (or mutants, if more than one amino acid is replaced), and the energy of the last accepted configuration is calculated. The Metropolis algorithm [Metropolis N. & Ulam S. *J. Am. Stat. Ass.* 44:335-341 (1949)] is used to determine whether the new trial sequence is accepted or rejected. If ΔE is negative, the mutation is accepted with the best rotamers, otherwise, the trial configuration is accepted at a probability determined according to the Boltzmann distribution $e^{-\Delta E/RT}$ (T being either a fixed or a varying annealing temperature as will be described hereinbelow).

The search continues through a large number of trials (steps) in order to allow the score to decrease and converge. This number depends on the size of the protein and on the number of residues that are allowed to be mutated (in case the design is just of a certain part of the protein).

It is possible to perform multiple mutations in each simulation step with adjustable probabilities to determine whether one or more mutations take place at any given trial step. If two or more mutations take place simultaneously, the minimal energy

score among all rotamer combinations of those mutations in the new sequence that has side chains of two or more virtual atoms, is searched.

Throughout the simulation, the lowest "scored" sequences are selected. The final optimal sequence is the one associated with the lowest total energy score found during the optimization process. The resulting sequence is then expanded to its corresponding 3D all-atom representation (as opposed to the virtual representation). This all atom representation may then be either saved in a computer readable form or extracted in the form of a computer output. Also collected are additional low energy score sequences, in order to enable analyzing relative consistency patterns of residues in a given position.

To evaluate whether the sequence obtained is indeed compatible with the predefined 3D structure, the all atom 3D model that is constructed from the novel sequence can be analyzed. There are several methods for determining whether a designed amino acid sequence indeed folds into a predefined 3D structure. One way of performing such an evaluation is to compare the structure of the designed protein (after standard all-atom minimization of its side chains with the structure of the model after molecular dynamics simulation in water or by comparing the molecular mechanics energy of the wild-type protein from which the 3D structure used, was taken, with that of the designed protein, after molecular dynamics of the latter. Molecular dynamics programs, such as CHARMM [Brooks, B.R. *et al. J. Comp. Chem.* 4:187-219 (1983)] may be utilized for this purpose, as illustrated in the following Examples.

The amino acid sequence designed by the method of the invention is a *de novo* sequence and preferably a sequence, which under physiological conditions folds substantially into the desired 3D structure. More preferably, the amino acid sequences obtained are biologically functional.

The sequence obtained may be used for various applications. According to one preferred embodiment, the designed amino acid sequence is chemically synthesized by procedures known in the art.

In a further preferred embodiment, the novel amino acid sequence is used to

create a nucleic acid sequence, such as DNA, which encodes the optimal sequence. A man versed in the art would know based on the existing technologies how to deduce at least one nucleic acid which will encode the amino acid sequence designed. The nucleic acid sequence obtained may then be cloned into a host cell and expressed. The
5 choice of codons, suitable expression vectors and suitable host cells may vary depending on a number of factors, and can be easily optimized as needed.

Once made, the novel amino acid sequence may be experimentally evaluated and tested for structure, function and stability, as required. This will be performed as is known in the art and will depend in part on the original protein from which the
10 sequence's backbone structure was taken. Preferably, the designed protein will be more stable than the known protein used as the starting point, although, at times, if some constraints are placed on the method disclosed herein, the designed sequence may be less stable. For example, it is possible to fix certain residues for altered biological activity and find the most stable sequence, but it may still be less stable than the wild
15 type protein. *Stable* in this context includes, but is not limited thereto, thermal stability, i.e. an increase in the temperature at which reversible or irreversible denaturing starts to occur; proteolytic stability, i.e. decrease in the amount of protein which is irreversibly cleaved in the presence of a particular protease (including autolysis); stability to alteration in pH or oxidative conditions; chelator stability; stability to metal
20 ions; stability to solvents such as organic solvents, surfactants, formulation chemicals, etc.

The proteins of the invention, and naturally, the nucleic acid deduced therefrom, may be used in a variety of applications, ranging from industrial to pharmacological uses, depending on the protein. Example of the different uses are in biotechnology
25 manufacturing of therapeutic peptides and proteins, in gene therapy, design of modified therapeutic peptides and proteins as pharmaceuticals, etc.

Another application of the invention disclosed herein may be the generation of a library of small stable protein elements that can be later assembled in various ways to design a sequence for a novel larger protein with a desired 3D structure. Yet further,

the method of the present invention may be applicable for optimizing the novel larger protein obtained thus ensuring that the peptides from which it was constructed indeed fit the structure.

In view of the above, the invention further provides amino acid sequences substantially compatible with a specified 3D structure, the amino acid sequences being obtained by the method of the present invention.

Yet further, in accordance with another of its aspect, there is provided a computer-based system for predicting an amino acid sequence compatible with a specified 3D structure, the system comprising the constituents as defined hereinbefore and after.

The input apparatus, such as a keyboard, employed by the system of the invention, are used for entering a selected set of coordinates representing the predefined 3D structure and other data such as scoring function and optimization process parameters. The first and third memory means being preferably a RAM (random access memory) are used for storing the initial and final data while the second memory means, being preferably a ROM (read-only memory) are used to store the program of the method of present invention. Further, the system comprises a microprocessor for performing, under control of the stored program, the steps of processing the entered data and displaying via a display unit or printer the novel amino acid sequence.

A user enters the coordinate set for the predefined 3D structure from an optional, auxiliary storage unit. In response to entry of the coordinate set, the system inputs the data for processing, stores the data in memory then processes it as described. The data provided regarding the 3D structures is typically retrieved from existing files known to those versed in the art and available to them.

SPECIFIC EXAMPLES

The present invention is defined by the claims, the contents of which are to be read as included within the disclosure of the specification, and will now be described by way of example with reference to the accompanying Figures.

5 GENERAL

CHARMM minimization and molecular dynamics

The comparison between the all-atom 3D structure of the designed protein (after minimization of its side chains) with its structure after molecular dynamics simulation is carried out in the following specific Examples using the CHARMM molecular dynamics
10 program [version 29, Brooks B.R. *et al.* (1983) *ibid.*]. Further, the comparison between the averaged energy of the designed protein after dynamics with the energy of the native protein is carried out using CHARMM forcefield [Mackerell A.D. *et al.* *J. Phys. Chem.* **102**:3586-3616 (1998)]. The minimization and the molecular dynamics are performed when the protein is embedded in a water sphere. For native proteins, the
15 coordinates are based on the information provided from PDB. The conformation of the designed protein is composed of the backbone conformation of the native protein and the side chains conformation of the new residues, according to the best rotamers chosen by the method of the invention.

CHARMM executes two minimization algorithms to the protein's side chains,
20 Steepest Descent (SD) and Adopted Basis Newton Raphson (ABNR). After the minimization of the side chains and of the water surrounding the protein, CHARMM performs molecular dynamics of the protein.

Example 1 – Zif268 as a target fold

In order to examined the method according to the invention the $\beta\beta\alpha$ motif
25 typified by the zinc finger DNA binding module in the zinc finger protein, Zif268 was used. Zif268 is a well recognized protein. This protein is small enough to be both computationally and experimentally tractable, yet large enough to form an

5

1.1 Solvent accessibility of Zif268

15

Table 1: Solvent Accessibility of Zif268

[illegible]

⁽¹⁾ Secondary structure containing Extended sheet (E), Turn (T) or Helix (H);

⁽²⁾ Zif268 wild-type sequence written in one letter code:

20

⁽⁴⁾ Solvent accessibility as determined by Dahiya and Mayo⁽¹³⁾.

As may be seen from Table 1, there are only two differences in Zif268 solvent accessibility obtained by one embodiment of the present invention and by D&M, the latter employing the connolly algorithm [Connolly M. L. Science **221**:709-713 (1983)] with subsequent manual changes in SA assignment of positions 1, 17 and 23 from the boundary class to the exposed class. Position 4 is classified as an intermediate residue by the present invention's algorithm and as an exposed residue in D&M's work, and position 7 is classified as an exposed residue by the present invention's algorithm and as an intermediate in D&M's work.

1.2 *The $\beta\beta\alpha$ motif optimization process of the energy score profile*

A Monte Carlo (MC) search was conducted as described hereinbefore and the profile of the score as a function of MC trials is calculated. The results which depended on the temperature of the system, T , are presented in Figures 1 and 2. Figure 1 presents the energy profile at three constant temperature parameters, 100K, 500K and 1000K. Figure 2 presents the energy profile using an annealing profile of the temperature parameters. The maximal temperatures were also 100K, 500K and 1000K and the periodicity was 500 Monte Carlo steps. Namely, during each cycle of 500 MC steps the temperature parameter is gradually reduced until it reaches zero, at which point the temperature parameter is set again to its initial value for a new 500 step annealing cycle to begin. The total size of the search space was 3.41×10^{43} but in all cases within less than 2000 iterations the algorithm reached the range of stable sequence between -270 kcal/mol and -300 kcal/mol, according to the scoring function.

It can be seen from Figs. 1 and 2 that the optimization reaches lower scores when the periodic annealing temperature profile is used. This profile enables the program to escape local minima by accepting high-energy sequences that would not be accepted, but at the same time, to optimize locally when the temperature is reduced. Among the three temperatures examined, the search reached the lowest values for the scoring function initial temperature parameter was 1000K and an annealing profile was used.

Figure 3 shows the energies of the 20 lowest sequences generated by the algorithm with different simulation lengths and different temperatures, using an annealing temperature profile with a periodicity of 500 Monte Carlo steps. The results show that at 500K the algorithm converges after 10^6 iterations, at 1000K after 10^5 and at 100K after 10^4 iterations and reached different energies each time.

The length of 10^6 iterations of the zinc finger protein simulation required one CPU hour on a single alpha processor workstation, and about 1.5 hours on Pentium III PC.

1.3 Results of $\beta\beta\alpha$ motif design

A total number of 50 simulations of the program were performed, each one terminated after 10^6 iterations under the same temperature conditions: an annealing temperature profile with an initial temperature of 1000K. Several different lengths of Monte Carlo steps periodicity were tested and it was found that the best annealing periodicity for a simulation of 10^6 iteration was 10^4 steps.

Each simulation began with a different random seed but, with the same 3D backbone template. The set of 50 simulations was repeated twice, each set with different solvent accessibility (SA) assignment for the protein residues. The first set used the present invention's automated solvent accessibility algorithm and the second set used Dahiyat and Mayo's (D&M) fitted assignments (see Table 1).

Tables 2A and 2B present the lowest energy sequences obtained in the first and second sets (A and B respectively), aligned with the second zinc finger module of the DNA binding protein *Zif268* and with D&M designed sequence, FSD-1. The coordinates used for the FSD-1 $\beta\beta\alpha$ motif score evaluations are the experimental NMR coordinates (PDB code 1FSD), which were found by D&M⁽¹³⁾. All the energy scores in Table 2B were calculated according the method of the present invention's reduced representation of amino acids and its scoring function. A and B scores were found to be lower than both *Zif268* score (without considering the His^2Cys^2 Zn-binding interactions which are not included in the scoring function), and the FSD-1 score. The

energy score of the most stable sequence, A, is -351.8kcal/mol. This score is lower than Zif268 score by 111.3kcal/mol which is a significant difference (not tacking into account the Zn interactions). The relative stability of both A and B sequences in comparison to the FSD-1 sequence, may be in part due to the fact the FSD-1 sequence was designed with a different scoring function.

Table 2A - The most stable sequence obtained for the Zinc finger

2 nd struc. ⁽¹⁾	E E E	T T	E E E	H H H H H H H H H H H
SA ⁽²⁾	i i b		i	i i i
D&M's SA ⁽²⁾	i b i		i	i i i
Position	5	10	15	20 25
FSD-1 ⁽³⁾	Q Q Y T A K I K G R T F R N E K E L R D F I E K F K G R			
Zif268 ⁽⁴⁾	K P F Q C R I C M R N F S R S D H L T T H I R T H T G E			
A ⁽⁵⁾	E H M F V H H H T T R F S S H T S F T S F L R S M Q G R			
B ⁽⁶⁾	Q H M T V H F H N T T F S H H S S L S T F L Q S F Q G R			

⁽¹⁾ Secondary structure containing Extended sheet (E), Turn (T) or Helix (H);

⁽²⁾ Solvent Accessibility as determined by the invention, categorized as buried (b), exposed (e) or intermediate (i) (all other positions are exposed);

⁽³⁾ The sequence as designed by D&M⁽¹³⁾;

⁽⁴⁾ Wild-type Zif268 sequence written in one letter code;

⁽⁵⁾ Sequence obtained by the present invention using the SA calculation described herein;

⁽⁶⁾ Sequence obtained by the present invention using D&M SA fixed assignments.

Table 2B – Energy scores of the sequences presented in Table 2A

Sequence	Energy (kcal/mol)
FSD-1 ⁽¹⁾	-166.5
Wild type Zif268 (no Zn ²⁺)	-240.6
A ⁽²⁾	-351.9
B ⁽³⁾	-348.7

⁽¹⁾ The sequence designed by D&M⁽¹³⁾;

⁽²⁾ The sequence obtained by the present invention using SA calculations as described.

⁽³⁾ The sequence obtained by the present invention using D&M SA fitted assignments.

5

1.4 Analysis of the resulting sequence

Statistical calculations over the 50 sequences obtained in 50 simulations (data not shown) provide the following observations:-

10

1. Even though all of the hydrophobic amino acids were allowed at the intermediate positions, the algorithm selected only non-polar amino acids at all those locations. This agrees well with the finding that these form a well-packed buried cluster [Dahiyat B. I. (1997), *ibid.*].

15

2. For positions 5, 8, 21, 25 of the original Zn-binding amino acids (two cysteines (C) and two histidines (H)), the algorithm consistently selected residues of a well defined solvent accessibility character (even at "intermediate" positions). Hydrophobic amino acids (Val, Phe, Leu, Ile, and Met) were selected for positions 5, 21 and 25 which are classified as either "buried" or "intermediate". In the single exposed position (position 8), a hydrophilic amino acid was selected (His).

20

3. Positions 21 and 25 of the optimal sequences were selected to be Phe or Met (position 21) and Leu (position 25) side chains. In the original Zif268, these positions were occupied by the zinc binding His residue.

These positions are more than 80 percent buried. Position 5, which is 100 percent buried, was predominantly selected to be Val. The other boundary positions demonstrate the steric constraints on buried residues by packing similar side chains to those of the original Zif268 sequence.

- 5 4. In the helix region (residues 15-26) the algorithm placed two Leu side chains and one Gln, which are good helix forming residues, in sequence B, and one Leu and one Gln in sequence A.
- 10 5. In both A and B sequences, position 5 on the exposed sheet surface was selected by the algorithm to be Val, which is a very good β -sheet forming residue, and positions 4 and 10 (and 11 only in sequence B) were selected to be Thr, which is also a good β -sheet forming residue.
- 15 6. Alignment of the optimal stable sequence (B) and Zif268 indicates that 4 out of 27 residues (not including residue 27 that remains Gly throughout the simulation) are identical (15%) and 11 are similar (including the identical 40.7%). D&M obtained similar values, with 5 identical residues (18.5%) and 12 similar (44.4%).
- 20 7. Alignment of the sequence B and FSD-1 indicates that 5 out of 27 residues are identical between the sequences (18.5%) and 11 are similar (including identical 40.7%).

20 1.5 *Secondary structure prediction of the designed sequence*

Sequence A and B were further examined by secondary structure prediction by the SSPAL predictor at Sanger Center [Salamov A. A. and Solovyev V. V. J. Mol. Biol. 247:11-15 (1995)], which enable to predict the secondary structure of a protein according to its primary structure (amino acid sequence). By these programs both A
25 and B sequences were predicted to have the desired Zinc finger motif. Table 3 presents the secondary structure of the native protein (Zif268) according to the Protein Data Bank (PDB), and A and B secondary structure prediction, according to SSPAL

algorithm at Sanger Centre. *A* was predicted to have one α -helix (designated H) and two β -strands (designated E)(the $\beta\beta\alpha$ motif) while the predicted secondary structure to *B* contained only one α -helix and one β -strand.

Table 3 – Secondary structure of predicted primary structures *A* and *B*.

Position	5	10	15	20	25
SS ⁽¹⁾ PDB	E E E	T T	E E E	H H H H H H H H H H H H	
Zif268	K P F Q C R I C M R N F S R S D H L T T H I R T H T G E				
SS ⁽¹⁾ <i>A</i>	E E E E	E E	H H H H H H H H H H H H		
<i>A</i>	E H M F V H H H T T R F S S H T S F T S F L R S M Q G R				
SS ⁽¹⁾ <i>B</i>	E E E E E E		H H H H H H H H		
<i>B</i>	Q H M T V H F H N T T F S H H S S L S T F L Q S F Q G R				

5 ⁽¹⁾ Secondary Structure

1.6 Molecular dynamics of the re-designed sequences

The reduced representation of the lowest energy designed sequences *A* and *B*, was expanded to an all-atom representation, using the molecular mechanics package CHARMM. The input for this experiment was the backbone coordinates of the native
10 protein, the new designed residues and the dihedral angles of each position along the designed sequence derived from the rotamer with the lowest energy score. The number of atoms of *A* and *B* after expansion to all atoms, were 459 and 446, respectively. Energy minimization was performed for *A* and *B*'s side chains as well as to Zif268 side chains using CHARMM forcefield, the SHAKE algorithm [Van Gunsteren W.F. &
15 Berendsen H.J.C. *Mol. Phys.* 34:1311 (1977)], a dielectric constant of $\epsilon=1$ and a 12Å energy cutoff. The minimization included 200 steps of SD (Steepest Descent) and then additional 500 steps of ABNR (Adopted Basis Newton Raphson). After minimization, each of the three structures were embedded in an 18Å water sphere which included ~1870 water molecules of type TIP3P [Jorgenes W.L. *et al.* *J Chem. Phys.* 79:926-935
20 (1983)]. Each of the water-protein systems of *A* and *B* were simulated for 500ps at

300K (with a 16Å energy cutoff) and a sample of 2000 conformations was collected from the resulting molecular dynamics trajectory. It was found that the secondary structure of the proteins was maintained during the molecular dynamic simulations.

The root-mean-square (rms) difference between the protein structure of the designed sequences before the molecular dynamics simulation and their protein structure after the molecular dynamics simulation was:-

Sequence:	Backbone:	Side Chains:	Total:
A	1.84Å	3.05 Å	2.69 Å
B	1.84Å	2.71Å	2.43Å

These results clearly indicate that the overall fold of the designed proteins remained $\beta\beta\alpha$ with some relaxation of backbone and side chains.

The molecular mechanics average energies of the two protein sequences during the simulations were:-

A:-	-437.4 kcal/mol
B:-	-196.4 kcal/mol

The above energy results indicate that the method and system of the present invention is indeed useful for the prediction of primary sequences that stabilize the $\beta\beta\alpha$ motif even in the absence of the ion.

The differences between the energy scores calculated for sequences A and B by the scoring function of the present invention and by the CHARMM force-field (after dynamics) were only 20% and 44%, respectively. these results indicate that the scoring function of the present invention provides a satisfactory evaluation to the potential energy of the designed sequences. Furthermore, in both CHARMM force-field and the scoring function of the present invention, sequence A yielded a significantly more stable structure than sequence B.

For comparison of the zinc bound wild-type Zif268 was also simulated using a system of solvated Zif268 wherein only the water sphere was allowed to move, while

the protein coordinates were kept fixed. The system was simulated for 100ps at 300K and a sample of 400 conformations was collected from the resulting molecular dynamics trajectory. The average CHARMM energy for *Zif268* was -1657.6 kcal/mol (Zn interaction with its four anchor residues contributing: ~-298.719 kcal/mol. The reason for the great difference with respect to the *Zif268* energy score by the function of the present invention compared to its CHARMM energy is that the scoring function calculation of the native protein does not consider the contribution of the His²Cys²Zn-binding interactions.

Figures 4A-4C show the 3D structure of *Zif268* as compared to that of the designed proteins *A* and *B* after minimization of their side chains, focusing on the core, which includes hydrophobic side chains in *A* and *B*, instead of the zinc ion chelated by two cysteines and two histidines in the native protein. The same structures are presented in Fig. 5 but with the core side chains displayed by spheres sized to the van der Waals radii of the atoms, which indicate the good packing of the core in the designed sequences.

Example 2 – G β 1 as a target fold

The core of β 1 domain of Streptococcal protein G (G β 1), a 56 residue protein, was examined. G β 1 is derived from a larger multi-domain cell surface protein that functions with high affinity binding to the Fc region of IgG. It comprises six β -strands and one α -helix. An extremely hyperthermophilic variant of the β 1 domain of Streptococcal protein G was already reported by Mayo and collaborators^(14,15).

2.1 Solvent accessibility for G β 1 domain

Solvent accessibility was evaluated as described in Example 1. A comparison of the results obtained by the method of the present invention and that of Malakauskas and Mayo (M&M⁽¹⁵⁾, using mainly the Connolly algorithm referred to hereinbefore) is presented in Figure 6. As can be seen from this Figure, 22 positions were found to be exposed in both cases, 11 were found to be buried and 10 in an intermediate level of solvent accessibility. The 13 remaining residues were classified differently in the two

methods. In 10 of these cases the discrepancy was between the subtle definition of a site as being "buried" or "intermediate". The solvent accessibility of the eighth position (position 8) selected for optimization was identical in two classification schemes.

5 2.2 Results of $G\beta 1$ core design

The energy score profile for $G\beta 1$ was obtained by the same manner as described for *Zif268*. Further, the energy score profile obtained for $G\beta 1$ was similar to that obtained for *Zif268* (Figs. 1 and 2), using the same temperature conditions. However, since only 8 out of 56 residues (14.3%) were mutated, the initial energy was already
10 negative while the final energies obtained were approximately -770 and -790 kcal/mol when an annealing temperature profile was used and the maximal value for the temperature parameter was 1000K.

Two sets of 50 simulations were conducted. In the first set of simulations, the non-mutated positions were kept in their native rotameric conformation while in the
15 second set of simulations, the rotameric states of the side chains of the non-mutating residues were allowed to change, thus providing a larger number of possible mutations and rotamer combinations. The total size of the search space in the first set was 1.06×10^{13} and in the second set was 2.52×10^{31} . Each simulation in the first set was terminated after 10^4 iterations with a maximal temperature of 1000K and an annealing
20 periodicity of 100 MC steps. Each simulation in the second set was terminated after 10^5 iterations, with a maximal temperature of 1000K and an annealing periodicity of 1000 MC steps.

Table 4 presents the mutated residues in the lowest energy sequences among the 50 simulations conducted for each set (C and D respectively).

Table 4 - Mutated residues

2 nd structure ⁽¹⁾	E	E		E	H	H		E	
Solvent accessibility	b	b	i	i	i	i	b	i	
Position	3	7	16	18	25	29	39	43	
<i>Gβ1</i>	Y	L	T	T	T	V	V	W	-676.4
<i>C</i>	L	L	L	F	L	L	V	M	-778.6
<i>D</i>	L	L	F	L	L	S	V	F	-788.8
<i>Gβ1-c3b4</i> ⁽³⁾	F	I	I	I	Q	I	I	I	

⁽¹⁾ E-β-sheet, H-helix;

⁽²⁾ Energy score by the scoring function of the present invention

⁽³⁾ Sequence designed by M&M⁽¹⁵⁾

5

2.3 Analysis of the resulting sequences

Statistical calculations over the 50 sequences obtained in 50 simulations in the fixed and non-fixed conformations, the latter having rotameric freedom (sets *C* and *D*, data not shown) provided the following observations:-

1. In 72%-76% of the sequences buried positions 7 and 39 were found to be Leu and Val, respectively, as in the native protein.
2. In most sequences Thr25 was mutated to Leu, which has a better helix propensity. Examining of sequences *C* and *D* by SSPAL predictor at Sanger Centre (as described hereinbefore) and by the PHD predictor at EMBL [Rost B and Sander C. J. Mol. Biol. 232:584-599 (1993)] showed that mutations T25L and V29L maintained the secondary structure of the α-helix.
3. More than 80% of the sequences consisted of the mutations T16L, T18L and T18F, which are located in a β-strand. The Leu and Phe apparently

15

can substitute from the wild-type Thr without compromising the β -sheet propensity.

4. The buried position 3 changed from Tyr mainly to Leu, which is more hydrophobic and is predicted to improve side chain packing in the interior of the protein.
5. Four percent of the 50 sequences in the first simulation set, where the coordinates of the non-mutated residues were kept fixed, had Trp in position 43, the same as in the native protein. In the second simulation set, this position was predominantly assigned with Phe residue.

10 2.4 Minimization of the redesigned sequences in comparison to native $G\beta 1$

The reduced representation of the designed sequence C, which was the sequence with the lowest energy score in the first set of simulations, where the conformation of 48 non-mutated residues was kept fixed, was expanded to its all-atom representation, using CHARMM [Brooks B.R. *et al.* (1983) *ibid.*], in the same manner as described
15 hereinbefore. In general, the information provided as input was the backbone coordinates of the native protein, the new residues and the rotamer dihedral angles at each position along the chain. The number of atoms in sequence C was 865. Energy minimization was performed for the side chains of this sequence as well as for $G\beta 1$'s side chains using CHARMM force-field [Mackerel A.D. *et al.* (1998) *ibid.*], a
20 dielectric constant $\epsilon=1$ and a 16Å energy cutoff. The minimization included 800 steps of SD and then additional 1100 steps of ABNR. The average energies of the sequences after minimization were:-

$G\beta 1$: -804.2 kcal/mol

C: -822.7 kcal/mol

The above results suggest that the mutations obtained by the methodology disclosed herein are tolerable which may lead to the designed of a more stable protein.

The difference between the energies of the native sequence G β 1 and sequence C, based on the present invention's scoring function and on CHARMM's force-field (after dynamics) were 7% and 16% respectively, which strengthens the conclusion that the method and system of the present invention provide a reliable tool for designing *de novo* proteins.

The above statement is further strengthened in light of Figure 7, which show a comparison of the 3D structure of G β 1 and sequence C.

These results show that re-designing five boundary residues and three buried positions in the core of β 1 domain of Streptococcal protein G was tolerable and that a stable, fully folded *de novo* protein may be obtained.

While the foregoing description disclosed in detail only a few specific embodiments of the invention, it will be understood by those skilled in the art that the method and system of the invention is not limited for the design of these proteins. Further, it should be understood that other variations of the method and system of the invention may be possible without departing from the scope and spirit of the invention as herein disclosed.

CLAIMS

1. A computer-implemented method for predicting at least one amino acid sequence compatible with a specified three-dimensional (3D) structure of a protein or peptide, which method comprises the steps of:-

- (a) providing a coordinate set representing the backbone of said 3D structure;
- (b) constructing a reduced virtual representation for the 3D structure provided in step (a);
- (c) determining for each position along the virtual structure representation provided in step (b) its solvent accessibility;
- (d) constructing an initial amino acid sequence by randomly assigning for each position along the structure an amino acid residue selected randomly from a predefined group of amino acids having a solvent accessibility compatible with the solvent accessibility of said position;
- (e) randomly selecting one or more positions along the sequence provided in step (d) and applying on each position a Monte-Carlo simulation in sequence space and rotamer space, said simulation comprising one or more scoring function calculating steps which include:-
 - i) randomly selecting one or more amino acid residues of the same solvent accessibility as that defined for said position to obtain a mutation;
 - ii) calculating an energy scoring function for each possible rotamer of each amino acid residue provided in step (i) based on their said reduced virtual representation;
 - iii) selecting the lowest scoring rotamer or when more than one amino acid is manipulated simultaneously, selecting the lowest

scoring rotamer combination;

- iv) determining whether to accept or reject the mutation with the rotamer or rotamer combination selected in step (iii); and
- v) assigning the amino acid residue or residues and their respective selected rotamer or rotamer combinations selected in step (iii) to said position/s and moving to another position along the sequence;

said simulation steps are repeated until for each position along said sequence, the residue and residue's rotamer with the lowest energy score is selected, to obtain a virtually represented amino acid sequence with the lowest total energy score;

- (f) expanding the reduced representation of the virtually represented amino acid sequence obtained in step (e) to its corresponding all-atom sequence representation thereby obtaining an amino acid sequence compatible with the predefined 3D structure.
- (g) optionally, creating a computer output of the expanded all-atom representation of the primary structure/s obtained in step (f).

2. The method as claimed in claim 1, wherein the 3D structure provided in step (a) is that of a native peptide, or protein, or of a designed protein.

3. The method as claimed in claim 1, wherein said coordinate set is provided in a computer readable form.

4. The method as claimed in claim 1, wherein said amino acid sequence may comprise naturally occurring amino acid residues, synthetic amino acid residues, or variations of said naturally occurring or synthetic amino acid residues.

5. The method as claimed in claim 1, wherein for each position along the 3D structure its solvent accessibility is determined according to the extent of exposure of said position to the solvent surrounding it, said position being either buried, exposed or

00422T 5248T 260

intermediate position.

6. The method as claimed in claim 5, wherein said solvent is substantially water.
7. The method as claimed in claim 6, wherein said buried positions are occupied by hydrophobic amino acid residues.
8. The method as claimed in claim 7, wherein said hydrophobic amino acid residues are selected from the group consisting of Ala, Tyr, Trp, Val, Leu, Ile, Phe, Met, Cys, Pro, Gly.
9. The method as claimed in claim 5, wherein said exposed positions are occupied by hydrophilic amino acid residues.
10. The method as claimed in claim 9, wherein said hydrophilic amino acid residues are selected from the group consisting of Lys, Arg, His, Glu, Asp, Gln, Asn, Ser, Thr.
11. The method as claimed in claim 5, wherein said intermediate positions are occupied by either hydrophilic or hydrophobic amino acid residues.
12. The method as claimed in claim 11, wherein said intermediate positions are occupied by amino acid residues selected from the group consisting of Pro, Lys, Arg, His, Glu, Asp, Gln, Asn, Ser, Thr, Gly, Ala, Tyr, Trp, Val, Leu, Ile, Phe, Met, Cys.
13. The method as claimed in claim 1, wherein said Monte Carlo simulation is applied simultaneously on up to three random positions in said sequence.
14. The method as claimed in claim 1, wherein said Monte Carlo step is conducted either at a fixed temperature or at a varying annealing temperature.
15. The method as claimed in claim 1, wherein a *de novo* amino acid sequence is generated.
16. The method as claimed in claim 1, wherein said amino acid sequence folds under physiological condition into a biologically functional 3D conformation substantially identical to said predefined 3D structure or to a portion thereof.

17. The method as claimed in claim 15 or 16, wherein said *de novo* amino acid sequence stabilized said 3D structure, as compared to the native amino acid sequence.
18. An amino acid sequence which folds under physiological conditions into a specified 3D structure, said amino acid sequence is obtained by the method of claim 1.
19. An amino acid sequence according to claim 18, which is biologically functional.
20. A nucleic acid sequence encoding the amino acid sequence of claim 19 or 20.
21. A computer-based system for predicting an amino acid sequence compatible with a predefined 3D structure according to the method of claim 1, said system comprising:-
 - (a) input apparatus for specifying said 3D structure;
 - (b) a first memory for storing the specified 3D structure;
 - (c) a second memory having a stored thereon an application program which when running, provides at least one amino acid sequence compatible with the specified 3D structure;
 - (d) a third memory for storing the at least one amino acid sequence obtained;
 - (e) a processor coupled to said input means, and to said first, second and third memories for representation of said amino acid sequence; and
 - (f) optionally, a display unit coupled to said processing means for displaying the amino acid sequence.

09718435 140400

ABSTRACT

A method for predicting an amino acid sequence compatible with a three-dimensional (3D) structure of a protein. A reduced virtual representation of the 3D structure is constructed, and, for each position along the representation, its solvent accessibility is determined. For each position along the structure, an amino acid residue is randomly selected from a predefined group of amino acids having a solvent accessibility compatible with the solvent accessibility of the position. A Monte-Carlo simulation is performed on this devised protein in which an amino acid at a particular position is sequentially replaced with other amino acids having the same solvent accessibility, and an energy score is calculated for each rotamer. The lowest scoring rotamer for this position is then selected. The Monte-Carlo simulation is repeated for each position along the sequence, to obtain an amino acid sequence with the lowest total energy score.

09718425-112400




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

DECLARATION FOR PATENT APPLICATION

Attorney Docket: 24460
Page 1 of 2

As a below-named inventor(s), I/we hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) is/are as stated below next to my/our name(s).

I/We believe I/we am/are the original inventor, first and sole (if only one name is listed below) or the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed, and for which a patent is sought on the invention entitled:

A METHOD AND SYSTEM FOR PREDICTING AMINO ACID SEQUENCES
COMPATIBLE WITH A SPECIFIED THREE DIMENSIONAL STRUCTURE

the specification of which: (check one)

☒ is attached hereto.☐ was filed on _____ as Serial No. _____

and was amended on _____ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application as defined by 37 CFR ' 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. ' 119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications:

(Application No.)	(Country)	(Day/Month/Year Filed)	Priority Claimed <input checked="" type="checkbox"/> <input type="checkbox"/> Yes No
137886	Israel	16/08/2000	<input checked="" type="checkbox"/> <input type="checkbox"/> Yes No
_____	_____	_____	<input type="checkbox"/> <input type="checkbox"/> Yes No
_____	_____	_____	<input type="checkbox"/> <input type="checkbox"/> Yes No

We hereby appoint Gary M. Nath, Reg. No. 26,965; Harold L. Novick, Reg. No. 26,011; Todd L. Juncos, Reg. No. 40,669; Lee C. Heiman, Reg. No. 41,827; Jerald L. Meyer, Reg. No. 41,194; Joshua B. Goldberg, Reg. No. 44,126; David R. Murphy, Reg. No. 22,751; Paul A. Sacher, Reg. No. 43,416; Deborah H. Yellin, 43,904; Nahid K. Usman, Reg. 47,148; and Roger Hahn, Reg. No. 46,376; as my attorneys to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct Telephone Calls to:

Send Correspondence to:

Gary M. Nath
(202) 775-8383NATH & ASSOCIATES, PLLC
Sixth Floor
1030 15th Street, N.W.
Washington, D.C. 20005 U.S.A.

020529

PATENT TRADEMARK OFFICE

We hereby claim the benefit under 35 U.S.C. ' 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by 35 U.S.C. ' 112, first paragraph, I/we acknowledge the duty to disclose material information as defined in 37 CFR ' 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. Application Serial No.)	(U.S. Filing Date)	(Status--patented, pending, abandoned)
_____	_____	_____
(U.S. Application Serial No.)	(U.S. Filing Date)	(Status--patented, pending, abandoned)
_____	_____	_____

Page 03

DECLARATION FOR PATENT APPLICATION

Attorney Docker 24460
Page 2 of 3

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that those statements are made with the knowledge that willful false statements made on oath are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and if such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Uma Baker

Investor's Signature [Signature] Date Nov 2, 2022

Residence: Herman Street 42, Migdalim, Ziv, 90805, Israel

Country of Citizenship: Israel

Post Office Address:

Full name of second inventor: Maya TOPE

Inventor's Signature: [Signature] Date: Nov 22, 2022

Residence: 44 Holland Street, Netanya 42211, Israel

Country of Citizenship: Israel

Post Office Address:

Full name of this inventor

Lawyer's Signature _____ **Date** _____

Residence.

Courtesy of Citizenship:

Post Office Address:

Full name of fourth investor:

Inventor's Signature _____ Date _____

Residence:

Country of Citizenship:

Post Office Address:

FULL name of fifth inventor:

Investigator's Signature _____ Date _____

Residence:

Country of Citizenship:

Post Office Address:

Full name of sixth lever:

Inventor's Signature _____ Date _____

Revisión.

Country of Citizenship:

Post Office Address: